Sanofi-aventis invests €150 million in France and continues its Change towards Biotechnologies

Sanofi-aventis invests €150 million in France and continues its Change towards Biotechnologies

Creation of the Group 3rd largest European vaccine production center in Neuville-sur-Saône

Biotechnology training programs for 700 employees

Steady number of industry jobs in France over the next four years
Paris, France - March 31, 2010 - Sanofi-aventis presented today to its social partners in France the project for investing and adapting its chemical and biotechnology manufacturing facilities in France over the next four years. The goal of the project includes the change of the sanofi-aventis chemical industrial activities in France towards biotechnology and vaccine production by 2014. The project also prepares the facilities for a decline in production that will follow patent expirations of several major drugs derived by synthetic chemistry.

"The change of our industrial network towards more biotechnologies corresponds to the evolution of innovation in the pharmaceutical world, more and more balanced between vaccines and compounds arising from biotechnologies, and active ingredients derived from synthetic chemistry", declared Philippe Luscan, Senior Vice President, Industrial Affairs, sanofi-aventis. "This project is fully in line with the Group's strategy and will allow sanofi-aventis to maintain its competitive advantage, to generate sustainable growth and to keep a steady number of industry jobs in France, over the next four years".

Sanofi-aventis will invest €150 million in its industrial plants, including € 90 million for the creation of a new innovative biosynthetic process in the industrial plants in Saint-Aubin-Lés-Elbeuf, in Seine-Maritime, France, and Vertolaye, in Puy de Dôme, France, in order to improve our corticosteroid production competitiveness at a global level. The new activities will result in local job creation.
Some new activities from Sanofi Pasteur would be housed in the new facility in Neuville-sur-Saône, Rhône, France, where the new vaccine against the dengue fever is already planned to be produced. This plant will become the Group's third largest European center fully dedicated to vaccines by 2014.

Sanofi-aventis' new plan also include a gradual phase-out of the facilities in Romainville, in Seine-Saint Denis, France, by the end of 2013, accompanied by a job stimulus plan to be implemented in the area.

The project will also includes measures to assist employees' geographic mobility, especially in the Paris and Lyon area labor basins, and to facilitate career mobility by means of biotechnology training programs for 700 employees, to be implemented in partnership with French Universities. No other change in the industrial network is planned within the same period.

Since 2008, sanofi-aventis has devoted a total of €700 million in investments to evolve its chemical production facilities in France to biotechnology capabilities - including the €350 million investment in Neuville-sur-Saône, and €200 million in Vitry-sur-Seine.
2 / 2
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward-Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.